Missense mutations in the gene isocitrate dehydrogenase one (IDH1) reprogram the metabolic and epigenetic landscape of IDH1 mutant (MT) gliomas making them molecularly and physiologically distinct from IDH1 wildtype (WT) gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.